BioAtla (BCAB)
(Delayed Data from NSDQ)
$1.73 USD
-0.03 (-1.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $1.81 +0.08 (4.62%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
BioAtla, Inc. [BCAB]
Reports for Purchase
Showing records 1 - 20 ( 33 total )
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Ozuriftamab?s HNSCC Potential Validated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Mixed First Look on Ozuriftamab; Lower PT to $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Impactful Catalysts in 2H23; Lower PT to $17; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Mecbotamab Vedotin?s NSCLC Potential Bolstered; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
3Q22: Additional Data in Lung Cancer Supports Lead Asset?s Activity
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Mecbotamab Vedotin Shows Promise in NSCLC; Lower PT to $20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
2Q22: Lung Cancer Initial Data Suggest Activity. Busy 2H22 Ahead.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Data During Upcoming Quarterly Call From Lead Program In NSCLC
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Mecbotamab Vedotin Scored First Two Sarcoma Indications; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
Company: BioAtla, Inc.
Industry: Medical - Biomedical and Genetics
A Disruptive Player in Cancer Therapy; Initiate With Buy and a $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department